Accès à distance ? S'identifier sur le proxy UCLouvain
Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: A randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Primary tabs
Document type | Article de périodique (Journal article) – Article de recherche |
---|---|
Access type | Accès restreint |
Publication date | 2013 |
Language | Anglais |
Journal information | "European Journal of Cancer" - Vol. 49, no. 4, p. 904-910 (2013) |
Peer reviewed | yes |
Publisher | Pergamon ((United Kingdom) Kidlington) |
issn | 0959-8049 |
e-issn | 1879-0852 |
Publication status | Publié |
Affiliations |
UCL
- SSS/IREC/MONT - Pôle Mont Godinne UCL - (MGD) Service d'hématologie |
Keywords | Bortezomib ; Clinical trial ; Follicular lymphoma ; Phase II ; Salvage therapy |
Links |
Bibliographic reference | Ribrag, V. ; Tilly, H. ; Casasnovas, O. ; Bosly, André ; Bouabdallah, R. ; et. al. Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: A randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). In: European Journal of Cancer, Vol. 49, no. 4, p. 904-910 (2013) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/124390 |